## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($61.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025**
- Source: WRIC ABC 8News | 20251207T000846 | Neutral | Relevance: 99%
-  Levi & Korsinsky LLP is urging investors of DexCom, Inc. (NASDAQ: DXCM) who suffered losses between January 8, 2024, and September 17, 2025, to act before December 26, 2025. A class action lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which defendants allegedly downplayed. The firm highlights its track record in securities litigation and invites affected shareholders to learn about their rights to recovery without cost or obligation.

**2. Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky to Join Class Action Before December 26, 2025**
- Source: FOX 2 | 20251207T160824 | Neutral | Relevance: 99%
- Levi & Korsinsky LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ:DXCM) for alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and presenting health risks, which the company allegedly downplayed. Shareholders who incurred losses during this period are encouraged to contact Levi & Korsinsky to learn about potentially recovering their losses.

**3. DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: FOX 2 | 20251208T130835 | Neutral | Relevance: 99%
-  Lieff Cabraser Heimann & Bernstein, LLP encourages DexCom, Inc. (NASDAQ:DXCM) investors who purchased securities between January 8, 2024, and September 17, 2025, to contact them regarding a pending securities class action. The lawsuit alleges that DexCom made false and misleading statements about design changes to its G6 and G7 continuous glucose monitoring systems, which were introduced without FDA approval and led to compromised accuracy and significant issues like app connectivity problems and delayed alerts. These issues resulted in substantial stock price declines and a $12.4 billion loss in market capitalization, prompting a December 26, 2025, lead plaintiff motion deadline.

**4. Pomerantz LLP Pursues Class Action Lawsuit Against DexCom, Inc. â€“ DXCM**
- Source: FOX 2 | 20251206T230811 | Neutral | Relevance: 99%
-  Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and its officers, alleging that the company made false and misleading statements about its G6 and G7 continuous glucose monitoring systems. The lawsuit claims DexCom made unauthorized design changes, resulting in less reliable devices and increased health risks for users. The firm seeks damages for investors who purchased DexCom securities between July 26, 2024, and September 17, 2025.

**5. DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM**
- Source: WBOY.com | 20251208T140805 | Neutral | Relevance: 99%
-  The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. (NASDAQ: DXCM) regarding a securities class action lawsuit. Investors who purchased DXCM shares between January 8, 2024, and September 17, 2025, are encouraged to contact the firm to discuss potential lead plaintiff appointment. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and presenting health risks, and that the company downplayed these issues.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |
| 2025-11-10 | Morgan Stanley | $63 | $89 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |
| 2025-11-10 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 12.4% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.85 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.7B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.85 |
| Forward P/E | 26.4 |
| Current P/E | 31.8 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 1.7% (minimal 5-day change). Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Outperforming sector by 5.1pp, stock-specific strength. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (0.89), confirming momentum. RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.73% (CS: 73) | Neutral |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 0.89 | Bullish |
| vs SMA20 | 1.070x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 0.876x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $65.62
- **Stop Loss:** $61.28 (6.6% risk)
- **Target:** $69.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 115
- **Position Value:** $7,546.30
- **Portfolio %:** 7.55%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*